Drug updated on 11/27/2023
|Tablet (emtricitabine/ rilpivirine/tenofovir alafenamide; 200 mg/25 mg/ 25 mg)
|Ongoing and Completed Studies
- Indicated as a complete regimen for the treatment of HIV-1 infection in patients weighing at least 35kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY.
Product Monograph / Prescribing Information
|Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) Prescribing Information.
|Gilead Sciences, Inc. Foster City, CA
Randomized Controlled Trials
|Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.